HomeCompareCHEK vs SBUX

CHEK vs SBUX: Dividend Comparison 2026

CHEK yields 119.05% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHEK wins by $8.08M in total portfolio value
10 years
CHEK
CHEK
● Live price
119.05%
Share price
$1.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.24M
Annual income
$3,108,090.72
Full CHEK calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — CHEK vs SBUX

📍 CHEK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHEKSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHEK + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHEK pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHEK
Annual income on $10K today (after 15% tax)
$10,119.05/yr
After 10yr DRIP, annual income (after tax)
$2,641,877.11/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, CHEK beats the other by $2,581,411.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHEK + SBUX for your $10,000?

CHEK: 50%SBUX: 50%
100% SBUX50/50100% CHEK
Portfolio after 10yr
$4.21M
Annual income
$1,589,613.59/yr
Blended yield
37.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CHEK
Analyst Ratings
4
Buy
2
Hold
Consensus: Buy
Altman Z
-715.9
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHEK buys
0
SBUX buys
0
No recent congressional trades found for CHEK or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHEKSBUX
Forward yield119.05%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$8.24M$167.0K
Annual income after 10y$3,108,090.72$71,136.45
Total dividends collected$7.49M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: CHEK vs SBUX ($10,000, DRIP)

YearCHEK PortfolioCHEK Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$22,605$11,904.76$11,121$420.68+$11.5KCHEK
2$49,337$25,149.94$12,548$648.40+$36.8KCHEK
3$104,092$51,301.04$14,440$1,013.98+$89.7KCHEK
4$212,533$101,154.53$17,068$1,617.30+$195.5KCHEK
5$420,434$193,023.94$20,912$2,649.52+$399.5KCHEK
6$806,726$356,861.32$26,875$4,499.29+$779.9KCHEK
7$1,503,143$639,946.75$36,771$8,014.12+$1.47MCHEK
8$2,722,746$1,114,383.27$54,542$15,197.11+$2.67MCHEK
9$4,799,842$1,886,503.76$89,602$31,242.49+$4.71MCHEK
10$8,243,922$3,108,090.72$167,011$71,136.45+$8.08MCHEK

CHEK vs SBUX: Complete Analysis 2026

CHEKStock

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Full CHEK Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CHEK vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHEK vs SCHDCHEK vs JEPICHEK vs OCHEK vs KOCHEK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.